Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-02-19
1995-08-22
Higel, Floyd D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514381, 548252, 548253, 548254, 5483235, 5483241, 5483245, 5483355, 5483381, A61K 31415, C07D23384, C07D23368, C07D23354, C07D40312
Patent
active
054440815
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to new substituted histidines which are angiotensin II receptor antagonists and are useful in regulating hypertension induced or exacerbated by angiotensin II and in the treatment of congestive heart failure, renal failure, and glaucoma. This invention also relates to pharmaceutical compositions containing substituted histidines and methods for using these compounds as antagonists of angiotensin II, as anti-hypertensive agents and as agents for treating congestive heart failure, renal failure, and glaucoma.
BACKGROUND OF THE INVENTION
The class of peptide pressor hormone known as angiotensin is responsible for a vasopressor action that is implicated in the etiology of hypertension in man. Inappropriate activity of the renin-angiotensin systems appears to be a key element in essential hypertension, congestive heart failure and in some forms of renal disease. In addition to a direct action on arteries and arterioles, angiotensin II (AII), being one of the mostpotent endogenous vasoconstrictors known, stimulates the release of aldosterone from the adrenal cortex. Therefore, the renin-angiotensin system, by virtue of its participation in the control of renal sodium handling, plays an important role in cardiovascular homostasis.
Interruption of the renin-angiotensin system with converting enzyme inhibitors, such as captopril, has proved to be clinically useful in the treatment of hypertension and congestive heart failure (Abrams, W. B., et al., (1984), Federation Proc., 43, 1314). The most direct approach towards inhibition of the renin- angiotensin system would block the action of AII at the receptor. Compelling evidence suggests that AII also contributes to renal vasoconstriction and sodium retention that is characteristic of a number of disorders such as heart failure, cirrhosis and complications of pregnancy (Hollenberg, N. K., (1984), J. Cardiovas. Pharmacol., 6, S176). In addition, recent animal studies suggest that inhibition of the renin-angiotensin system may be beneficial in halting or slowing the progression of chronic renal failure (Anderson, S., et al., (1985), J. Clin. Invest., 76, 612). Also, a recent patent application (South African Patent Application Number 87/01, 653) claims that AII antagonists are useful as agents for reducing and controlling elevated intraocular pressure, especially glaucoma, in mammals.
The compounds of this invention inhibit, block and antagonize the action of the hormone AII, and are therefore useful in regulating and moderating angiotensin induced hypertension, congestive heart failure, renal failure, glaucoma, and other disorders attributed to the actions of AII. When compounds of this invention are administered to mammals, the elevated blood pressure due to AII is reduced and other manifestations based on AII intercession are minimized and controlled. Compounds of this invention is also expected to exhibit diuretic activity.
Recognition of the importance of blocking and inhibiting the actions of AII has stimulated other efforts to synthesize antagonists of AII. The following references have disclosed imidazole derivatives which are described as having AII blocking activity and useful as hypotensive agents.
U.S. Pat. No. 4,340,598 discloses substituted imidazol-5-yl alkanoic acids, and amido and lower-alkyl ester derivatives thereof, of the formula: ##STR2## wherein R.sup.1 is lower alkyl or phenylC.sub.1-2 alkyl optionally substituted with halogen or nitro; R.sup.2 is lower alkyl, cycloalkyl, or phenyl optionally substituted; one of R.sup.3 and R.sup.4 is --(CH.sub.2).sub.n COR.sup.5, where R.sup.5 is amino, lower alkoxy or hydroxy and n is 0-2, and the other of R.sup.3 and R.sup.4 is hydrogen or halogen. Examples include 1-benzyl-2-n-butyl-4-chloroimidazole-5-acetamide and 1-benzyl-2-n-butyl-5-chloroimidazole-4-acetic acid.
U.S. Pat. No. 4,355,040 discloses substituted 1-benzylimidazol-5-yl acetic acid derivatives having the formula: ##STR3## wherein R.sup.1 is lower alkyl, cycloalkyl, or phenyl optionally substituted; X.sup.1, X.sup
REFERENCES:
patent: 4215217 (1980-07-01), Lewis et al.
patent: 4324792 (1982-04-01), Bradshaw et al.
patent: 4340598 (1982-07-01), Furukawa et al.
patent: 4348404 (1982-09-01), Whitney
patent: 4355040 (1982-10-01), Furukawa et al.
patent: 4404387 (1983-09-01), Gall
patent: 4612324 (1986-09-01), Cashin et al.
patent: 4898878 (1990-02-01), Shapiro et al.
patent: 4996221 (1991-02-01), Melmon et al.
patent: 5034539 (1991-07-01), Arrang et al.
patent: 5159083 (1992-10-01), Thurkauf et al.
patent: 5191086 (1993-02-01), Poss
Gleason John G.
Hempel Judith
Hill David T.
Samanen James
Weinstock Joseph
Higel Floyd D.
Lentz Edward T.
McCarthy Mary E.
SmithKline Beecham Corp
Venetianer Stephen
LandOfFree
Substituted histidines having angiotension II receptor antagonis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted histidines having angiotension II receptor antagonis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted histidines having angiotension II receptor antagonis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2142153